Due to the frequent activation of the PI3K/AKT/mTOR pathway in a variety of tumor types, it has become an important target for cancer therapies, and a variety of drugs targeting PI3K, AKT, or mTOR are currently on the market or under development [23]. This evidence concerns the gene AKT1 and neoplasm.